Amylin Patent-Cliff Exposure & CMS Drug Spending Portfolio

Amylin (US): 1 reconciled FDA prescription therapies, $28.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$28.1M
2024 Medicare Part D Spend$15.9M
2024 Medicaid Spend$12.2M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel